Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.

Agostina StradellaMelissa JohnsonSanjay GoelHaeseong ParkNehal LakhaniHendrik-Tobias ArkenauMatthew D GalskyEmiliano CalvoVicente BazVictor MorenoOmar SaavedraStephen J LuenSong MuQiting WanVictoria ChangWa ZhangMinal Barve

Published in: Cancer medicine (2024)

Pamiparib in combination with TMZ had a manageable safety profile. Further investigation of the efficacy of this combination in tumor types with specific DNA damage repair deficiencies is warranted.

Keyphrases

dna damage
squamous cell carcinoma
locally advanced
small cell lung cancer
oxidative stress
rectal cancer
neoadjuvant chemotherapy
dna repair
newly diagnosed